Home > Name List By 1 > 1-[4-(3-methylanilino)pyridin-3-yl]sulfonyl-3-propan-2-ylurea Canada

CAS No 56211-40-6 , 1-[4-(3-methylanilino)pyridin-3-yl]sulfonyl-3-propan-2-ylurea Search by region : Canada

  • Name: 1-[4-(3-methylanilino)pyridin-3-yl]sulfonyl-3-propan-2-ylurea
  • Synonyms: 56211-40-6; Luprac; Torasemida [INN-Spanish]; Torasemidum;1-[4-(3-methylanilino)pyridin-3-yl]sulfonyl-3-propan-2-ylurea; Torasemida; Torasemidum [INN-Latin]; Demadex;Torasemide;
  • CAS Registry Number:
  • Melting Point: 163-164 ºC
  • Density: 1.283 g/cm3
  • Refractive index: 1.594
  • Safety Statements: 26-37/39
  • Hazard Symbols: Xi: Irritant;
  • Molecular Weight: 348.42
  • InchiKey: NGBFQHCMQULJNZ-UHFFFAOYSA-N
  • InChI: InChI=1S/C16H20N4O3S/c1-11(2)18-16(21)20-24(22,
    23)15-10-17-8-7-14(15)19-13-6-4-5-12(3)9-13/h4-11H,1-3H3,(H,17,19)(H2,
    18,20,21)
  • Risk Statements: 36-36/37/38
  • Molecular Formula: C16H20N4O3S
  • Molecular Structure:CAS No:56211-40-6 1-[4-(3-methylanilino)pyridin-3-yl]sulfonyl-3-propan-2-ylurea

Select to

56211-40-6 TORSEMIDE

  • Canada Synth?se AptoChem Inc. [Manufacturer]
  • Tel: 514-496-4252
  • Fax: 514-496-4253
  • Address: Synth?se AptoChem Inc.
    6100 Royalmount Ave
    Montreal, QC
    Canada
    H4P 2R2 null,nullCanada
Contact Supplier

Select to

References of 1-[4-(3-methylanilino)pyridin-3-yl]sulfonyl-3-propan-2-ylurea
Title: Torsemide
CAS Registry Number: 56211-40-6
CAS Name: N-[[(1-Methylethyl)amino]carbonyl]-4-[(3-methylphenyl)amino]-3-pyridinesulfonamide
Synonyms: 1-isopropyl-3-[(4-m-toluidino-3-pyridyl)sulfonyl]urea; 3-isopropylcarbamylsulfonamido-4-(3¢-methylphenyl)aminopyridine; torasemide
Manufacturers' Codes: AC-4464; BM-02015; JDL-464
Trademarks: Demadex (Roche); Toradiur (Roche); Torem (Roche); Unat (Roche)
Molecular Formula: C16H20N4O3S
Molecular Weight: 348.42
Percent Composition: C 55.16%, H 5.79%, N 16.08%, O 13.78%, S 9.20%
Literature References: Sulfonylurea loop diuretic. Prepn: J. E. DeLarge et al., DE 2516025; eidem, US 4018929 (1975, 1977 both to A. Christiaens, S.A.); J. DeLarge, C. L. Lapiere, Ann. Pharm. Fr. 36, 369 (1978). Pharmacokinetics in humans: M. Lesne et al., Int. J. Clin. Pharmacol. Ther. Toxicol. 20, 382 (1982). Preliminary evaluation in acute heart failure: R. Stroobandt et al., Arch. Int. Pharmacodyn. 260, 151 (1982). Clinical pharmacology: D. C. Brater et al., Clin. Pharmacol. Ther. 42, 187 (1987). Series of articles on pharmacology, mode of action and renal effects in animals: Arzneim.-Forsch. 35, 1520-1541 (1985); on pharmacology, pharmacokinetics and clinical studies: Eur. J. Clin. Pharmacol. 31, Suppl., 1-55 (1986); Arzneim.-Forsch. 38, 143-214 (1988). Clinical comparison with furosemide, q.v., in congestive heart failure: J. Cosin et al., Eur. J. Heart Fail. 4, 507 (2002).
Properties: mp 163-164°. pKa 6.44.
Melting point: mp 163-164°
pKa: pKa 6.44
Therap-Cat: Diuretic.
Keywords: Diuretic; Sulfonamide Derivatives.